ES2116583T3 - Compuestos azaciclicos, composiciones que los contienen y su uso como antagonistas de taquicininas. - Google Patents

Compuestos azaciclicos, composiciones que los contienen y su uso como antagonistas de taquicininas.

Info

Publication number
ES2116583T3
ES2116583T3 ES94907565T ES94907565T ES2116583T3 ES 2116583 T3 ES2116583 T3 ES 2116583T3 ES 94907565 T ES94907565 T ES 94907565T ES 94907565 T ES94907565 T ES 94907565T ES 2116583 T3 ES2116583 T3 ES 2116583T3
Authority
ES
Spain
Prior art keywords
sup
sub
compounds
replaced
rent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94907565T
Other languages
English (en)
Inventor
Raymond Baker
Christopher John Swain
Brian John Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939303243A external-priority patent/GB9303243D0/en
Priority claimed from GB939322150A external-priority patent/GB9322150D0/en
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2116583T3 publication Critical patent/ES2116583T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE A COMPUESTOS DE LA FORMULA (I), Y SALES Y PRODROGAS DE LOS MISMOS, EN LA QUE N ES 1, 2 O 3 Y DONDE ALGUN ATOMO DE CARBONO DE (CH{SUB,2}){SUB,N} PUEDE SER SUSTITUIDO POR R{SUP,4} Y/O R{SUP,5}; X REPRESENTA O O S; R{SUP,1} REPRESENTA FENILO (CH{SUB,2}){SUB,Q} OPCIONALMENTE SUSTITUIDO, ARILO, HETEROARILO, BENCIHIDRILO O BENCILO; R{SUP,4} Y R{SUP,5} CADA UNO REPRESENTA INDEPENDIENTEMENTE H, HALO, ALQUILOC{SUB,1-6}, OXO, CO{SUB,2}R{SUP,A} O CONR{SUP,A}R{SUP,B}, R{SUP,6} REPRESENTA H O ALQUILOC{SUB,1-6}; R{SUP,7} REPRESENTA ALQUILOC{SUB,1-6} O FENILO OPCIONALMENTE SUSTITUIDO; R{SUP,8} REPRESENTA H, COR{SUP,A}, CO{SUB,2}R{SUP,A}, COCONR{SUP,A}R{SUP,B}, COCO{SUB,2}R{SUP,A}, ALQUILO C{SUB,1-6} OPCIONALMENTE SUSTITUIDO POR UNA VARIEDAD DE SUSTITUYENTES, O ALQUILOC{SUB,1-6} OPCIONALMENTE SUSTITUIDO POR OXO, SUSTITUIDO POR UN HETREOCICLO AROMATICO OPCIONALMENTE SUSTITUIDO. LOS COMPUESTOS SON ANTAGONISTAS DE LA TACIQUININA UTILES PARA EL TRATAMIENTO DEL DOLOR O LA INFLAMACION, MIGRAÑA O EMESIS.
ES94907565T 1993-02-18 1994-02-10 Compuestos azaciclicos, composiciones que los contienen y su uso como antagonistas de taquicininas. Expired - Lifetime ES2116583T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939303243A GB9303243D0 (en) 1993-02-18 1993-02-18 Therapeutic agents
GB939322150A GB9322150D0 (en) 1993-10-27 1993-10-27 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2116583T3 true ES2116583T3 (es) 1998-07-16

Family

ID=26302480

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94907565T Expired - Lifetime ES2116583T3 (es) 1993-02-18 1994-02-10 Compuestos azaciclicos, composiciones que los contienen y su uso como antagonistas de taquicininas.

Country Status (9)

Country Link
US (1) US5633266A (es)
EP (1) EP0683767B1 (es)
JP (1) JPH08506823A (es)
AT (1) ATE166867T1 (es)
AU (1) AU679207B2 (es)
CA (1) CA2152925A1 (es)
DE (1) DE69410784T2 (es)
ES (1) ES2116583T3 (es)
WO (1) WO1994019323A1 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ATE170174T1 (de) * 1994-01-13 1998-09-15 Merck Sharp & Dohme Gem-bissubstituierte azazyclische tachykinin- antagonisten
GB9402688D0 (en) * 1994-02-11 1994-04-06 Merck Sharp & Dohme Therapeutic agents
JPH10500944A (ja) * 1994-05-05 1998-01-27 メルク シヤープ エンド ドーム リミテツド モルホリン誘導体及びタキキニンのアンタゴニストとしてのそれらの使用
DE19504627A1 (de) * 1995-02-13 1996-08-14 Bayer Ag Verfahren und neue Zwischenprodukte zur Herstellung von Triazolinonen
GB9513117D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
GB9513121D0 (en) * 1995-06-28 1995-08-30 Merck Sharp & Dohme Therapeutic agents
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
KR100885986B1 (ko) 1999-11-03 2009-03-03 에이엠알 테크놀로지, 인크. 노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2001095904A1 (en) * 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
US7407480B2 (en) * 2001-07-27 2008-08-05 Ams Research Corporation Method and apparatus for correction of urinary and gynecological pathologies, including treatment of incontinence cystocele
WO2003101459A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
JPWO2006030975A1 (ja) * 2004-09-17 2008-05-15 武田薬品工業株式会社 ピペリジン誘導体およびその用途
WO2006115285A1 (ja) * 2005-04-21 2006-11-02 Takeda Pharmaceutical Company Limited 医薬組成物
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
ZA200800440B (en) 2005-07-15 2009-12-30 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2805945B1 (en) 2007-01-10 2019-04-03 MSD Italia S.r.l. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8258306B2 (en) * 2007-12-12 2012-09-04 Amgen Inc. Glycine transporter-1 inhibitors
KR20100126467A (ko) 2008-03-03 2010-12-01 타이거 파마테크 티로신 키나아제 억제제
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2025008409A2 (en) 2023-07-03 2025-01-09 Preeti Jha Substituted 2-phenylpiperidine compounds for use in the diagnosis, treatment and/or prevention of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033439B2 (ja) * 1980-03-07 1985-08-02 財団法人相模中央化学研究所 ジペプチドの製造方法
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
EP0499313B1 (en) * 1991-02-11 1997-06-11 MERCK SHARP & DOHME LTD. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
CA2112397A1 (en) * 1991-08-20 1993-03-04 Raymond Baker Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
AU675786B2 (en) * 1992-04-15 1997-02-20 Merck Sharp & Dohme Limited Azacyclic compounds
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists

Also Published As

Publication number Publication date
WO1994019323A1 (en) 1994-09-01
CA2152925A1 (en) 1994-09-01
AU679207B2 (en) 1997-06-26
DE69410784D1 (de) 1998-07-09
JPH08506823A (ja) 1996-07-23
DE69410784T2 (de) 1999-01-14
AU6109394A (en) 1994-09-14
ATE166867T1 (de) 1998-06-15
US5633266A (en) 1997-05-27
EP0683767A1 (en) 1995-11-29
EP0683767B1 (en) 1998-06-03

Similar Documents

Publication Publication Date Title
ES2116583T3 (es) Compuestos azaciclicos, composiciones que los contienen y su uso como antagonistas de taquicininas.
AR025225A1 (es) Feniloxazolidinonas heterociclicas biciclicas sustituidas antibacterianas y composiciones farmacéuticas
ES2185665T3 (es) Derivados de benzofurano como antagonistas de taquicininas.
UY27952A1 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
CO4900068A1 (es) Piperazina di - n - sustituidas y piperidinas 1,4 -di- sustituidas utiles como antagonistas muscarinicos
DOP2004001062A (es) Compuestos utiles en terapia
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
NO166129C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-9h-pyrido (3,4-b)indoler.
AR028624A1 (es) Heterociclilalquilaminas como antagonistas de receptores muscarinicos
MX9302948A (es) Imidazolinonas fungicidas y composicion fungicida que las contiene.
UY25211A1 (es) Inhibidores de isoquinolinilguanidina uroquinasa
ES2141383T3 (es) Derivados de benzoatos biciclicos de piperidinilo sustituido en n.
ES2054811T3 (es) Derivados de tetrahidroisoquinolin-2-ilo como antagonistas de tromboxano a2.
PE108798A1 (es) Compuestos de naftilo, intermedios, composiciones y procedimientos de uso
PE51294A1 (es) Derivado de benzofurano, proceso para su preparacion y composicion farmaceutica que lo contiene
ES2045440T3 (es) Aminocetales, su preparacon y su utilizacion como fungicidas.
ES2145306T3 (es) Nitro-benzamidas utiles como agentes anti-arritmicos.
ES2058874T3 (es) 1-acil-2-pirrolidinonas como mejoradores del entendimiento y memoria y composiciones farmaceuticas que las contienen.
AR010200A1 (es) Derivados de aza-antraciclinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
LT2086B (lt) -difenil-4-aril-4-oksi-1-piperidinbutanamido-n-oksidu arba ju stereoizomeru gavimo budas
ES2081111T3 (es) Derivados de n-hidroxiurea que inhiben la lipoxigenasa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 683767

Country of ref document: ES